SYRE today
$103.58-$3.24 (-3.03%)close Nov 12, 2026Trend
DailyUptrend (starting)
4 hourLeaning Bearish
1 hourDescending Triangle
15 minBearish
5 minSymmetric Triangle
Daily trend turns down below $76.87
Key levels
Resistance$145.50
Resistance$110.17
Support$100.42
Support$92.77
Latest news & SEC filings
AnalystWedbush keeps Outperform on Spyre Therapeutics, cuts price target
AnalystGuggenheim keeps Buy rating on Spyre Therapeutics, lifts target to $135
All SYRE news →About Spyre Therapeutics
Spyre Therapeutics develops antibody-based medicines for inflammatory bowel disease and rheumatic conditions. Its candidates are engineered for long half-life and target alpha-4-beta-7, TL1A, and IL-23, given alone or in pairs. Mid-stage studies are underway in ulcerative colitis and in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. The company is based in the United States.
Based on the company's 10-K filed Feb 19, 2026.
Nasdaq · Healthcare
Spyre Therapeutics, Inc. (SYRE)
What Is the Price Target for SYRE?
SEPT Low Target
$80.00
SEPT Mid Target
$117.50
SEPT High Target
$130.00
Analyst Consensus
$117.50
Is SYRE a Buy or Sell Right Now?
Thesis
- •Revenue growing -62.0% YoY with ACCELERATING trend — accelerating momentum.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for SYRE.
Start Free Trial →Is SYRE Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$117.50
27
Moat Score
NONE
3/9
Piotroski Score
N/A
Altman Z-Score
What Is Smart Money Doing with SYRE?
Insider Signal
SELLING
0 buys / 16 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Sloan Sheldon | officer | Buy | 8,333 | $229K | Jun 3, 2026 |
| Sloan Sheldon | officer | Sale | 8,333 | $625K | Jun 3, 2026 |
| Turtle Cameron | director officer | Sale | 3,557 | $247K | Jun 1, 2026 |
| Turtle Cameron | director officer | Sale | 8,149 | $575K | Jun 1, 2026 |
| Turtle Cameron | director officer | Sale | 3,294 | $235K | Jun 1, 2026 |
| Burrows Scott L | officer | Buy | 7,500 | $109K | Jun 1, 2026 |
| Burrows Scott L | officer | Sale | 1,801 | $126K | Jun 1, 2026 |
| Burrows Scott L | officer | Sale | 2,599 | $184K | Jun 1, 2026 |
| Burrows Scott L | officer | Sale | 3,100 | $223K | Jun 1, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →SYRE Growth Story
Revenue YoY
-62.0%
3yr Revenue CAGR
N/A%
EPS Growth YoY
N/A
FCF Growth YoY
N/A%
Revenue Trend
ACCELERATING
Dark Pool Trades for SYRE
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for SYRE, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:07:19 | $103.48 | 1,200 | $$124K | BUY |
| 20:00:20 | $103.39 | 1,100 | $$114K | BUY |
| 19:56:22 | $103.54 | 1,100 | $$114K | BUY |
| 19:53:52 | $103.54 | 1,100 | $$114K | BUY |
| 19:49:56 | $103.48 | 1,000 | $$103K | BUY |
5 dark pool trades shown · $$569K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Spyre Therapeutics, Inc. (SYRE) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →SYRE — frequently asked questions
What is SYRE stock price today?
Spyre Therapeutics, Inc. (SYRE) is at $103.58, down 3.03% (-$3.24) at the Nov 12, 2026 close.
Why is SYRE stock moving today?
Latest SYRE news — Nov 4, 2026: Wedbush keeps Outperform on Spyre Therapeutics, cuts price target · Nov 4, 2026: Guggenheim keeps Buy rating on Spyre Therapeutics, lifts target to $135
What is the SYRE price target?
The average analyst price target for SYRE is $117.50, ranging from $80 to $130, based on 16 analysts. Latest: Spyre Therapeutics maintains on Oct 19, 2026.
What do analysts rate SYRE?
Analyst ratings for SYRE: 0 Buy, 31 Hold, 1 Sell — consensus Hold.
Did SYRE beat earnings?
SYRE last reported on Aug 4, 2026: EPS -$0.36 vs -$0.76 expected — a beat of 52.6%.
Does SYRE pay a dividend?
SYRE does not currently pay a dividend.
What are SYRE support and resistance levels?
Support: $100.42, $92.77, $86.62. Resistance: $110.17, $145.50, $168.50.
What are insiders doing with SYRE?
Insider activity: SELLING, 0 buys and 16 sells in the last 90 days.
What is the latest news on SYRE?
Nov 4, 2026: Wedbush keeps Outperform on Spyre Therapeutics, cuts price target · Nov 4, 2026: Guggenheim keeps Buy rating on Spyre Therapeutics, lifts target to $135